{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:43:26Z","timestamp":1772484206179,"version":"3.50.1"},"reference-count":63,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Adapting to different smoking cessation medications when an individual has not stopped smoking has shown promise, but efficacy has not been tested in racial and ethnic minority individuals who smoke and tend to have less success in quitting and bear a disproportionate share of tobacco-related morbidity and mortality.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate efficacy of multiple smoking cessation pharmacotherapy adaptations based on treatment response in Black adults who smoke daily.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This randomized clinical trial of adapted therapy (ADT) or enhanced usual care (UC) included non-Hispanic Black adults who smoke and was conducted from May 2019 to January 2022 at a federally qualified health center in Kansas City, Missouri. Data analysis took place from March 2022 to January 2023.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Both groups received 18 weeks of pharmacotherapy with long-term follow-up through week 26. The ADT group consisted of 196 individuals who received a nicotine patch (NP) and up to 2 pharmacotherapy adaptations, with a first switch to varenicline at week 2 and, if needed, a second switch to bupropion plus NP (bupropion\u2009+\u2009NP) based on carbon monoxide (CO)-verified smoking status (CO\u2009\u22656 ppm) at week 6. The UC group consisted of 196 individuals who received NP throughout the duration of treatment.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Anabasine-verified and anatabine-verified point-prevalence abstinence at week 12 (primary end point) and weeks 18 and 26 (secondary end points). The \u03c72<\/jats:sup> test was used to compare verified abstinence at week 12 (primary end point) and weeks 18 and 26 (secondary end points) between ADT and UC. A post hoc sensitivity analysis of smoking abstinence at week 12 was performed with multiple imputation using a monotone logistic regression with treatment and gender as covariates to impute the missing data.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 392 participants who were enrolled (mean [SD] age, 53 [11.6] years; 224 [57%] female; 186 [47%] \u2264\u2009100% federal poverty level; mean [SD] 13 [12.4] cigarettes per day), 324 (83%) completed the trial. Overall, 196 individuals were randomized to each study group. Using intent-to-treat and imputing missing data as participants who smoke, verified 7-day abstinence was not significantly different by treatment group at 12 weeks (ADT: 34 of 196 [17.4%]; UC: 23 of 196 [11.7%]; odds ratio [OR], 1.58; 95% CI,\u20090.89-2.80; P<\/jats:italic>\u2009=\u2009.12), 18 weeks (ADT: 32 of 196 [16.3%]; UC: 31 of 196 [15.8%]; OR, 1.04; 95% CI, 0.61-1.78; P<\/jats:italic>\u2009=\u2009.89), and 26 weeks (ADT: 24 of 196 [12.2%]; UC: 26 of 196 [13.3%]; OR, 0.91; 95% CI, 0.50-1.65; P<\/jats:italic>\u2009=\u2009.76). Of the ADT participants who received pharmacotherapy adaptations (135\/188 [71.8%]), 11 of 135 (8.1%) were abstinent at week 12. Controlling for treatment, individuals who responded to treatment and had CO-verified abstinence at week 2 had 4.6 times greater odds of being abstinent at week 12 (37 of 129 [28.7%] abstinence) than those who did not respond to treatment (19 of 245 [7.8%] abstinence; OR; 4.6; 95% CI, 2.5-8.6; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial of adapted vs standard of care pharmacotherapy, adaptation to varenicline and\/or bupropion\u2009+\u2009NP after failure of NP monotherapy did not significantly improve abstinence rates for Black adults who smoke relative to those who continued treatment with NP. Those who achieved abstinence in the first 2 weeks of the study were significantly more likely to achieve later abstinence, highlighting early treatment response as an important area for preemptive intervention.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03897439<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.17895","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T15:08:42Z","timestamp":1687273722000},"page":"e2317895","source":"Crossref","is-referenced-by-count":10,"title":["Multiple Pharmacotherapy Adaptations for Smoking Cessation Based on Treatment Response in Black Adults Who Smoke"],"prefix":"10.1001","volume":"6","author":[{"given":"Nicole L.","family":"Nollen","sequence":"first","affiliation":[{"name":"Department of Population Health and the University of Kansas Cancer Center, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasjit S.","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Mayo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science and the University of Kansas Cancer Center, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward F.","family":"Ellerbeck","sequence":"additional","affiliation":[{"name":"Department of Population Health and the University of Kansas Cancer Center, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor L. S.","family":"Leavens","sequence":"additional","affiliation":[{"name":"Department of Population Health and the University of Kansas Cancer Center, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Salzman","sequence":"additional","affiliation":[{"name":"Department(s) of Internal Medicine, Division of Respiratory and Critical Care, University of Missouri\u2013Kansas City School of Medicine, University Health, Kansas City, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denton","family":"Shanks","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Woodward","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Allen","family":"Greiner","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Sanderson","family":"Cox","sequence":"additional","affiliation":[{"name":"Department of Population Health and the University of Kansas Cancer Center, University of Kansas School of Medicine, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"issue":"11","key":"zoi230540r1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.15585\/mmwr.mm7111a1","article-title":"Tobacco product use among adults\u2014United States, 2020.","volume":"71","author":"Cornelius","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi230540r2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3322\/caac.v72.3","article-title":"Cancer statistics for African American\/Black People 2022.","volume":"72","author":"Giaquinto","year":"2022"},{"key":"zoi230540r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2022.06.021","article-title":"Widening disparities in cigarette smoking by race\/ethnicity across education level in the United States.","volume":"139","author":"Nguyen-Grozavu","year":"2020","journal-title":"Preventive medicine"},{"issue":"17","key":"zoi230540r4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.15585\/mmwr.mm6617e1","article-title":"Vital signs: racial disparities in age-specific mortality among Blacks or African Americans\u2014United States, 1999-2015.","volume":"66","author":"Cunningham","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi230540r6","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/j.clinthera.2009.08.029","article-title":"Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers.","volume":"31","author":"Ferguson","year":"2009","journal-title":"Clin Ther"},{"issue":"5","key":"zoi230540r7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0149-2918(01)80023-0","article-title":"Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.","volume":"23","author":"Jamerson","year":"2001","journal-title":"Clin Ther"},{"issue":"8","key":"zoi230540r8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jama.1994.03510320029025","article-title":"Predicting smoking cessation: who will quit with and without the nicotine patch.","volume":"271","author":"Kenford","year":"1994","journal-title":"JAMA"},{"issue":"5","key":"zoi230540r9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1089\/cap.2011.0073","article-title":"SMARTer discontinuation trial designs for developing an adaptive treatment strategy.","volume":"22","author":"Almirall","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"zoi230540r10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s13142-014-0265-0","article-title":"Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research.","volume":"4","author":"Almirall","year":"2014","journal-title":"Transl Behav Med"},{"issue":"21","key":"zoi230540r11","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Placebo-free designs for evaluating new mental health treatments: the use of adaptive treatment strategies.","volume":"23","author":"Dawson","year":"2004","journal-title":"Stat Med"},{"issue":"4","key":"zoi230540r12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/1740774514525691","article-title":"SMART designs in cancer research: past, present, and future.","volume":"11","author":"Kidwell","year":"2014","journal-title":"Clin Trials"},{"issue":"498","key":"zoi230540r13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/01621459.2011.641416","article-title":"Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer.","volume":"107","author":"Wang","year":"2012","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"zoi230540r14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/add.v111.1","article-title":"Comparative effectiveness of motivation phase intervention components for use with smokers unwilling to quit: a factorial screening experiment.","volume":"111","author":"Cook","year":"2016","journal-title":"Addiction"},{"issue":"2","key":"zoi230540r15","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.amepre.2017.01.038","article-title":"Effectiveness of switching smoking-cessation medications following relapse.","volume":"53","author":"Heckman","year":"2017","journal-title":"Am J Prev Med"},{"issue":"1","key":"zoi230540r16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/add.v111.1","article-title":"Identifying effective intervention components for smoking cessation: a factorial screening experiment.","volume":"111","author":"Piper","year":"2016","journal-title":"Addiction"},{"issue":"8","key":"zoi230540r17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1176\/appi.ajp.2013.12070919","article-title":"Adapting smoking cessation treatment according to initial response to precessation nicotine patch.","volume":"170","author":"Rose","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"11","key":"zoi230540r18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1176\/appi.ajp.2014.13050595","article-title":"Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.","volume":"171","author":"Rose","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi230540r19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/add.v111.1","article-title":"Comparative effectiveness of intervention components for producing long-term abstinence from smoking: a factorial screening experiment.","volume":"111","author":"Schlam","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"zoi230540r20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/add.2004.99.issue-1","article-title":"Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy.","volume":"99","author":"Shiffman","year":"2004","journal-title":"Addiction"},{"issue":"20","key":"zoi230540r21","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1001\/archinternmed.2009.355","article-title":"The impact of repeated cycles of pharmacotherapy on smoking cessation: a longitudinal cohort study.","volume":"169","author":"Cupertino","year":"2009","journal-title":"Arch Intern Med"},{"issue":"3","key":"zoi230540r23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.15212\/FMCH.2017.0138","article-title":"Tobacco cessation pharmacotherapy use among racial\/ethnic minorities in the United States: considerations for primary care.","volume":"5","author":"Hooper","year":"2017","journal-title":"Fam Med Community Health"},{"issue":"5","key":"zoi230540r24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.5993\/AJHB.36.5.4","article-title":"African American smokers\u2019 intention to use pharmacotherapy for cessation.","volume":"36","author":"Lynam","year":"2012","journal-title":"Am J Health Behav"},{"issue":"3","key":"zoi230540r25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/jnci\/djab208","article-title":"Smoking cessation prevalence and inequalities in the United States: 2014-2019.","volume":"114","author":"Leventhal","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"10077","key":"zoi230540r26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(17)30569-X","article-title":"Structural racism and health inequities in the USA: evidence and interventions.","volume":"389","author":"Bailey","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"zoi230540r27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1377\/hlthaff.2019.01394","article-title":"The ACA's impact on racial and ethnic disparities in health insurance coverage and access to care.","volume":"39","author":"Buchmueller","year":"2020","journal-title":"Health Affairs"},{"issue":"5","key":"zoi230540r29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/phr\/116.5.404","article-title":"Racial residential segregation: a fundamental cause of racial disparities in health.","volume":"116","author":"Williams","year":"2001","journal-title":"Public Health Reports"},{"issue":"1","key":"zoi230540r30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/nyas.1999.896.issue-1","article-title":"Race, socioeconomic status, and health: the added effects of racism and discrimination.","volume":"896","author":"Williams","year":"1999","journal-title":"Annals NY Acad Sci"},{"issue":"8","key":"zoi230540r31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0027-9684(15)30405-3","article-title":"Health care provider tobacco cessation counseling among current African American tobacco users.","volume":"103","author":"Palmer","year":"2011","journal-title":"J Nat Med Assoc"},{"issue":"2","key":"zoi230540r32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/MLR.0b013e31827310a1","article-title":"Prior experiences of racial discrimination and racial differences in health care system distrust.","volume":"51","author":"Armstrong","year":"2013","journal-title":"Med Care"},{"key":"zoi230540r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.101032","article-title":"Protocol from a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in African Americans who smoke.","volume":"30","author":"Nollen","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"9","key":"zoi230540r34","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/ntr\/ntab040","article-title":"Patterns of non-cigarette tobacco and nicotine use among current cigarette smokers and recent quitters: findings from the 2020 ITC four country smoking and vaping survey.","volume":"23","author":"Li","year":"2021","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"zoi230540r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.32053","article-title":"Assessment of racial differences in pharmacotherapy efficacy for smoking cessation: secondary analysis of the EAGLES randomized clinical trial.","volume":"4","author":"Nollen","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi230540r37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1111\/add.v112.8","article-title":"Extended treatment for cigarette smoking cessation: a randomized control trial.","volume":"112","author":"Laude","year":"2017","journal-title":"Addiction"},{"issue":"7","key":"zoi230540r38","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/j.1360-0443.2011.03441.x","article-title":"Relative performance of common biochemical indicators in detecting cigarette smoking.","volume":"106","author":"Marrone","year":"2011","journal-title":"Addiction"},{"issue":"3","key":"zoi230540r39","first-page":"333","article-title":"Randomized controlled trial of group-based culturally specific cognitive behavioral therapy among African American smokers.","volume":"19","author":"Webb Hooper","year":"2017","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"zoi230540r40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"zoi230540r41","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/ntr\/ntr063","article-title":"A pilot clinical trial of varenicline for smoking cessation in black smokers.","volume":"13","author":"Nollen","year":"2011","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"zoi230540r42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pbb.2008.10.016","article-title":"Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.","volume":"92","author":"Schnoll","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"zoi230540r43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.7326\/0003-4819-152-3-201002020-00005","article-title":"Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial.","volume":"152","author":"Schnoll","year":"2010","journal-title":"Ann Intern Med"},{"issue":"10","key":"zoi230540r44","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/abm\/kax059","article-title":"A randomized controlled trial of an optimized smoking treatment delivered in primary care.","volume":"52","author":"Piper","year":"2018","journal-title":"Ann Behav Med"},{"key":"zoi230540r45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.addbeh.2014.11.012","article-title":"Smoking cessation abstinence goal in treatment-seeking smokers.","volume":"42","author":"Hall","year":"2015","journal-title":"Addict Behav"},{"issue":"3","key":"zoi230540r46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14622200701188919","article-title":"Effects of abstinence from tobacco: valid symptoms and time course.","volume":"9","author":"Hughes","year":"2007","journal-title":"Nicotine Tob Res"},{"key":"zoi230540r47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06298.x","article-title":"The clinical significance of drug craving.","volume":"1248","author":"Tiffany","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"zoi230540r48","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1037\/a0015270","article-title":"Timeline follow-back versus global self-reports of tobacco smoking: a comparison of findings with nondaily smokers.","volume":"23","author":"Harris","year":"2009","journal-title":"Psychol Addict Behav"},{"issue":"2","key":"zoi230540r49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1037\/0893-164X.12.2.101","article-title":"Reliability and validity of a smoking timeline follow-back interview.","volume":"12","author":"Brown","year":"1998","journal-title":"Psychol Addict Behav"},{"issue":"12","key":"zoi230540r50","first-page":"1668","article-title":"Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy.","volume":"11","author":"Jacob","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"zoi230540r51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1525-1497.1998.00001.x","article-title":"Smoking cessation among inner-city African Americans using the nicotine transdermal patch.","volume":"13","author":"Ahluwalia","year":"1998","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi230540r52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jsat.2009.01.006","article-title":"Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking.","volume":"37","author":"Gariti","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi230540r53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S2213-2600(14)70294-2","article-title":"A randomized placebo-controlled trial to test a genetically-informed biomarker for personalizing treatment for tobacco dependence.","volume":"3","author":"Lerman","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"3","key":"zoi230540r54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/add.2005.100.issue-3","article-title":"Outcome criteria in smoking cessation trials: proposal for a common standard.","volume":"100","author":"West","year":"2005","journal-title":"Addiction"},{"issue":"11","key":"zoi230540r55","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/add.2010.105.issue-11","article-title":"Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.","volume":"105","author":"Gonzales","year":"2010","journal-title":"Addiction"},{"issue":"6","key":"zoi230540r56","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/2167702621994551","article-title":"Barriers to building more effective treatments: negative interactions amongst smoking intervention components.","volume":"9","author":"Baker","year":"2021","journal-title":"Clin Psychol Sci"},{"issue":"4","key":"zoi230540r57","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s13142-014-0278-8","article-title":"Five population-based interventions for smoking cessation: a MOST trial.","volume":"4","author":"Fraser","year":"2014","journal-title":"Transl Behav Med"},{"issue":"7","key":"zoi230540r58","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1808779","article-title":"A randomized trial of e-cigarettes vs nicotine-replacement therapy.","volume":"380","author":"Hajek","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi230540r59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010216.pub5","article-title":"Electronic cigarettes for smoking cessation.","volume":"4","author":"Hartmann-Boyce","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"zoi230540r60","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.26324","article-title":"Effect of pod e-cigarettes vs cigarettes on carcinogen exposure among African American and Latinx smokers: a randomized clinical trial.","volume":"3","author":"Pulvers","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi230540r61","article-title":"E-cigarettes to augment stop smoking in-person support and treatment with varenicline (E-ASSIST): a pragmatic randomized controlled trial.","author":"Tattan-Birch","year":"2022","journal-title":"Nicotine Tob Res"},{"issue":"2","key":"zoi230540r62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1090198115599396","article-title":"Promoting health by addressing basic needs: effect of problem resolution on contacting health referrals.","volume":"43","author":"Thompson","year":"2016","journal-title":"Health Educ Behav"},{"issue":"1","key":"zoi230540r63","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S2213-2600(19)30269-3","article-title":"Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial.","volume":"8","author":"Walker","year":"2020","journal-title":"Lancet Respir Med"},{"key":"zoi230540r35","volume-title":"Treating Tobacco Use and Dependence Clinical Practice Guideline: 2008 Update","author":"Fiore","year":"2008"},{"key":"zoi230540r5","unstructured":"US National Cancer Institute. A socioecological approach to addressing tobacco-related health disparities. National Cancer Institute Tobacco Control Monograph 22. Accessed May 4, 2023. https:\/\/cancercontrol.cancer.gov\/sites\/default\/files\/2020-08\/m22_complete.pdf"},{"key":"zoi230540r22","unstructured":"2019 National survey on drug use and health: African Americans. Substance Abuse and Mental Health Services Administration. Accessed May 11, 2023. https:\/\/www.samhsa.gov\/data\/"},{"key":"zoi230540r28","unstructured":"Semega? J, Kollar? M, Creamer? J, Mohanty? A. US Census Bureau, current population reports, P60-266, income and poverty in the United States: 2018. US Census Bureau. Accessed May 15, 2023. https:\/\/www.census.gov\/library\/publications\/2019\/demo\/p60-266.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2806291\/nollen_2023_oi_230540_1686669886.79948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T15:08:51Z","timestamp":1687273731000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2806291"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.17895","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}